Company ProfilePremium

Daejung Chemicals & Metals Co., Ltd.

Company Profile Analysis

Ticker: 120240.KQ대정화금 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
Daejung Chemicals & Metals Co., Ltd. - Company showcase

Year Founded & Workforce

1968

201 Employees

Daejung Chemicals & Metals Co., Ltd. logo

Daejung Chemicals & Metals Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Daejung Chemicals & Metals Co., Ltd. Overview

Daejung Chemicals & Metals is a small-cap Korean specialty chemical manufacturer that has built a niche in laboratory reagents, high-purity and HPLC-grade solvents, electronic-grade solvents and pharmaceutical excipient-type active ingredients. The company sells to a fragmented base of research institutes, universities, hospitals, chemical producers and pharmaceutical manufacturers, and supplements its own catalogue of roughly 2,000 manufactured items with resale of some 20,000 imported global-brand products. Revenue reached a record KRW 108.1 bn in FY2025, with an operating margin of about 10%, and trailing-twelve-month operating income to June 2026 climbed to roughly KRW 15.9 bn. The balance sheet is conservatively funded, holding about KRW 75.7 bn of cash and short-term deposits against only KRW 6.9 bn of borrowings at end-FY2025. Family-controlled and trading near half of book value, the company is a cash-rich, low-growth compounder whose 50:50 joint venture with SK Chemicals gives it a foothold in semiconductor and OLED solvent supply chains.


What the company does

Daejung manufactures and distributes chemical reagents (substances used to detect, measure or react with other materials in laboratory, quality-control and industrial settings) and a smaller line of pharmaceutical raw materials. According to the business description in its DART filings, as summarized by ValueLine (26.2Q update), the company produces general, analytical, diagnostic and specialty test reagents, electronic-grade solvents and pharmaceutical raw materials for domestic and overseas customers. Its main products are various alcohols, acetonitrile, tetrahydrofuran (THF) and ethyl acetate.

The company's filings divide the business into two reporting areas:

  1. Reagent business — chemicals used for detection and quantification reactions in R&D, bio-industry and environmental testing, plus higher-volume industrial and electronic-grade solvents.

  2. Pharmaceutical raw materials (API) business — research, manufacture and supply of raw materials, principally excipient-type ingredients, to finished-drug manufacturers.

Morningstar's profile lists four business areas: Reagents, Raw materials for medicines, New materials, and Order-made (custom) synthesis. It cites acetaldehyde, acetamide, HPLC solvents and benzyl alcohol as example products. The Chemknock industrial directory lists further business areas: electronic materials, veterinary drug ingredients and food additives.

Business and revenue model

Revenue stream (2Q26 revenue basis, Butler)Share of revenue
Other manufactured products (aggregated)51%
Merchandise (resold third-party goods)38%
Tetrahydrofuran4%
Ethyl acetate4%
n-Hexane4%

The revenue model is almost entirely product sales. There is no subscription, licensing or service revenue of any significance. Two product streams drive sales:

Manufactured products ("products"): reagents, solvents and API materials made at the Siheung site. Named large-volume lines include THF, ethyl acetate and n-hexane, each about 4% of 2Q26 revenue (Butler, product mix based on the 1H26 report).

Merchandise ("goods", 상품): resale of third-party reagents and laboratory chemicals. These were about 38% of 2Q26 revenue (Butler). The 2019 eBest brief described the company as stock-selling about 20,000 products from major global makers alongside about 2,000 of its own manufactured items.

Note: shares sum to about 101% because of rounding in the source.

Value-chain position

Daejung sits in the mid-stream of the fine-chemicals value chain. It buys commodity or technical-grade feedstocks such as solvents and inorganic salts, purifies, formulates and packages them to reagent, HPLC, electronic or pharmacopoeia grades, and sells them in small lots (laboratory) or larger lots (industrial and electronic solvents, API). Raw materials accounted for about KRW 41.4 bn of FY2025 cost of sales of KRW 85.5 bn, or roughly 48%. This makes feedstock pricing and purification yields the main gross-margin drivers. Labour inside cost of sales was about KRW 5.5 bn, and depreciation about KRW 3.1 bn (ValueLine cost breakdown, FY2025).

Customer types and end-markets

Customer groupExamples named in filings/pressDemand driver
Chemical and materials companiesLG Chem, Hanmi Fine Chemical, Hyosung (DART business summary via ValueLine)Process solvents, QC reagents, electronic-grade solvents
Pharmaceutical manufacturersChong Kun Dang, Boryung, Korea United Pharm (ValueLine); Celltrion, Kyongbo Pharm (Financial News, Aug 2021, citing DART)API/excipient raw materials, HPLC solvents, QC reagents
Research institutes, universities, hospitalsNamed as core demand base by eBest (2019)Analytical and general reagents
Electronics (semiconductor/OLED)Addressed mainly via the SK Chemicals Daejung JV (Dealsite, Aug 2020)High-purity solvents

Independent characterization

Daejung is best understood as a high-mix, low-volume domestic reagent house with a growing industrial-solvent tail. Its moat rests on catalogue breadth, regulatory and quality approvals, local logistics for hazardous materials, and long customer relationships, not on proprietary technology. R&D spending is modest at about 1.6% of revenue. Growth has historically tracked the Korean reagent market: eBest reported a 2009–2018 sales CAGR of 7.9% against 7.7% for the domestic reagent market. Profitability is mid-single-digit to low-double-digit at the operating line and is supplemented by meaningful interest income on a large cash pile. The step-up in 1H26 earnings suggests operating leverage is available when volumes rise. Gross margin sits around 21–23%, below the mid-20s levels of 2016–2018, which points to a mix shift toward lower-margin merchandise and bulk solvents.

Strategy

Stated strategy themes

The reviewed sources do not provide verbatim strategy text from the FY2025 annual report or an investor day. The company holds no regular earnings calls and has no sell-side coverage. The themes below are drawn from company disclosures and profiles:

Customer-centric, environment-first, open management: The company positioned 2016 as a fresh start around customer respect, environmental priority and open management (Chemknock corporate profile, paraphrased).

Electronic-materials localization: eBest (2019) identified acceleration of import substitution in electronic materials as a key momentum driver, together with expansion of domestic pharma R&D.

Partnership-led entry into high-purity solvents: The 2020 SK Chemicals JV was explicitly aimed at improving high-purity solvent technology for semiconductors and OLED and at developing the reagent business (Dealsite, 2020).

Initiatives in the last 24 months

DateInitiativeDetailTargets
26 Mar 2026Corporate Value-up Plan (voluntary disclosure)Filed under the Korea Exchange value-up program. The disclosure states the company meets the high-dividend company criteria of the Restriction of Special Taxation Act: payout of 25% or more and dividend growth of 10% or more (FY2025 payout 25.1%, total dividend +13.1%). Dividends from such companies qualify for separate taxation at 14–30% for individual investors.Detailed ROE, PBR or payout targets not available in reviewed sources
Feb 2026Dividend increaseFY2025 DPS raised 13.1% to KRW 475—
FY2025–1H26Capacity and working-capital buildCapex rose to KRW 3.8 bn (TTM Jun-2026) from KRW 1.5 bn (FY2025); construction in progress KRW 1.5 bn; inventory buildProject specifics not disclosed

ESG and sustainability commitments: Not publicly disclosed.

Cost programs: Not publicly disclosed.

Medium-term financial targets and guidance

None publicly disclosed. The company does not issue earnings guidance.

Products & Services

Daejung does not publish prices, launch dates or version years for individual reagents. All pricing models are "not publicly disclosed." Catalogue items are sold per unit (bottle or drum) through direct sales and distributors. The catalogue below is compiled from Simply Wall St (S&P Global description), Morningstar, ValueLine (DART business summary), Chemknock and eBest.

Reagent segment — own-manufactured products

Product lineDescription and key specificationsTarget customerNamed flagship items
General analytical reagents — organicLaboratory-grade organic chemicals for synthesis, extraction and analysisUniversities, research institutes, corporate labsAcetaldehyde, acetamide, benzyl alcohol (Morningstar)
General analytical reagents — inorganicInorganic salts, acids and bases at reagent gradeLabs, QC departmentsNot individually named in reviewed sources
IndicatorsAcid-base, redox and complexometric indicatorsAnalytical and teaching labsNot individually named
High-purity reagentsHigher-assay grades with tighter impurity limitsAnalytical labs, pharma QCNot individually named
pH standard solutionsCalibrated buffer solutions for pH meter calibrationQC labs, environmental labspH standard solution (S&P Global description)
Normal (volumetric) solutionsStandardized titrants of defined normalityTitration-based QCNormal solutions
Karl Fischer moisture reagentsReagents for water-content determinationPharma, petrochemical and food QCKF moisture reagents
HPLC solventsLow-UV-absorbance, low-residue solvents for liquid chromatographyPharma and biotech analytical labs, CROsAcetonitrile, methanol, THF (HPLC grade)
Toxic and heavy-metal test reagentsReagents for mineral and heavy-metal toxicity analysisEnvironmental and food-safety testing labsHeavy-metal test reagents
Pesticide residue detection reagentsResidue-analysis grade solvents and reagentsFood-safety and agricultural testingPesticide-residue reagents
Electronic-grade reagentsLow-metal, low-particle grades for electronics processesElectronics and display makersElectronic-grade reagents (S&P Global description)
Diagnostic reagentsReagents for clinical and diagnostic testing (eBest category)Hospitals, diagnostic labsNot individually named

Reagent segment — bulk and industrial solvents

ProductUseDisclosed revenue weight
Tetrahydrofuran (THF)Polymer, pharmaceutical and HPLC solventAbout 4% of 2Q26 revenue
Ethyl acetateExtraction, coatings and pharmaceutical processingAbout 4% of 2Q26 revenue
n-HexaneExtraction and chromatography solventAbout 4% of 2Q26 revenue
AcetonitrileHPLC and pharmaceutical synthesis solventNamed main product (DART summary); weight not disclosed
Methyl alcohol (methanol)HPLC and general solventNamed product; weight not disclosed
Other alcoholsVarious gradesNamed main product group; weight not disclosed

Reagent segment — merchandise (resale)

LineDescriptionScale
Global-brand reagent distributionStock sales of products from major international reagent makersAbout 20,000 SKUs (eBest, 2019); about 38% of 2Q26 revenue

Pharmaceutical raw materials (API) segment

LineDescriptionCustomers
Excipient-type APIsRaw materials used as excipients or inputs in finished-dose drugsChong Kun Dang, Boryung, Korea United Pharm, Celltrion, Kyongbo Pharm (named in filings and press)
Specific APIsMorningstar cites benzyl alcohol and acetamide as product examples. Company staff stated in 2020 that Daejung does not produce dexamethasone itself but imports it when needed (Dealsite, Aug 2020).Pharma manufacturers

Other business areas (per directory and Morningstar profiles)

AreaStatus
New materials / electronic materialsListed as business area; JV with SK Chemicals targets semiconductor and OLED high-purity solvents
Order-made (custom) synthesisListed by Morningstar; scale not disclosed
Veterinary drug raw materialsListed by Chemknock; scale not disclosed
Food additivesListed by Chemknock; scale not disclosed

Financial Narrative

All figures are separate K-IFRS, KRW bn unless stated. Source: DART annual reports FY2021–FY2025 as compiled by ETF Shopping and ValueLine; FY2025 detail and 1H26 trailing figures from ValueLine (DART 26.2Q update). Diluted EPS equals basic EPS; no dilutive instruments were identified.

Income statement

FY2025 income-statement detail (ValueLine, DART):

EBITDA note: ValueLine displays FY2025 EBITDA of KRW 17.6 bn. That figure does not reconcile with operating income plus reported depreciation and amortization (KRW 34.2 bn PP&E depreciation and 1.3 bn amortization in 억원 terms, i.e., KRW 3.4 bn and 0.1 bn).

Commentary:

Revenue: Revenue grew steadily from KRW 60.9 bn (FY2016) to KRW 96.6 bn (FY2022), then stalled for two years (FY2023 −3.4%, FY2024 −1.0%). That stall coincided with post-pandemic normalization of pharma and lab demand and weaker solvent prices. FY2025 broke out to a record KRW 108.1 bn (+17.1%), and momentum continued into 2026: TTM revenue to June 2026 reached KRW 119.3 bn.

Gross margin: Gross margin structurally compressed from about 25% (FY2016–FY2017) to about 20–23% (FY2021–FY2025). This is consistent with a rising share of merchandise and bulk solvents, and with feedstock inflation in 2021. FY2025 gross margin of 20.9% was flat on FY2024 despite higher volumes. TTM gross margin to June 2026 improved to about 22.7% (KRW 27.1 bn on KRW 119.3 bn).

Operating leverage: SG&A is largely fixed, rising only from about KRW 10.7 bn (TTM Jun-2025) to KRW 11.2 bn (TTM Jun-2026) while revenue grew about 23%. As a result, TTM operating income jumped to KRW 15.9 bn and the TTM operating margin to 13.3%.

Below-the-line earnings: Interest income on cash and deposits (KRW 2.8 bn in FY2025) and associate-related gains (KRW 1.5 bn) push net income above operating income. These items lifted net margin to 12.5% in FY2025.

Interim and trailing performance (1H26)

Q2 2025 is derived by the analyst from the change in ValueLine trailing-twelve-month series between March and June 2026, using the Q2 2026 reported figures (ETF Shopping). Treat as indicative.

Balance sheet

FY2021 balance sheet line items were not available in the sources reviewed. Four fiscal years are shown, with 1H26 in a separate table.

Net debt is calculated by the analyst as total debt minus cash and short-term financial instruments; small lease liabilities are excluded. ETF Shopping reports liabilities-to-equity of 21% for FY2021.

1H26 balance sheet (30 June 2026, KRW bn): total assets 220.5; cash 34.6; short-term financial instruments 48.9; inventories 18.6; trade receivables 18.6; PP&E 90.7 (construction in progress 1.5); short-term borrowings 6.9; total liabilities 31.8; equity 188.7; book value per share KRW 26,245; net cash about 76.6.

Commentary:

Liquidity: Liquid resources (cash plus short-term deposits) rose from KRW 46.4 bn (FY2022) to KRW 75.7 bn (FY2025) and KRW 83.5 bn (1H26). That is about 80% of the current market capitalization.

Leverage: Borrowings are minimal at KRW 6.9 bn, after a KRW 2.0 bn short-term loan repayment in 2025. No long-term debt or bonds are outstanding.

2023 balance-sheet step-up: In FY2023, land rose about KRW 9.3 bn and capital surplus about KRW 9.9 bn with an unchanged share count, while new machinery was commissioned. The accounting driver of the capital-surplus increase was not identified in reviewed sources and is flagged for verification against the FY2023 annual report notes.

Working capital in 1H26: Inventory jumped from KRW 14.3 bn to KRW 18.6 bn (+30%), with finished products at KRW 8.3 bn and raw materials at KRW 6.6 bn. This supports higher sales but warrants monitoring.

Cash flow

Full five-year cash-flow statements were not available in the sources reviewed. The available verified series are shown below.

Source: ETF Shopping (DART), ValueLine.

Commentary. Cash conversion was weaker in FY2025: operating cash flow of KRW 10.0 bn was 74% of net income, as receivables (−KRW 3.0 bn) and inventory (−KRW 2.6 bn) absorbed cash during the revenue surge. It recovered strongly in the TTM to June 2026, with operating cash flow of KRW 16.0 bn, or 94% of net income. Capex is light, at about 1.4% of revenue in FY2025 and about 3.2% in TTM 1H26. The FY2023 cash decline (−KRW 17.6 bn) mainly reflects the reallocation of cash into short-term deposits (+KRW 32.4 bn) plus the capacity investment; total liquidity actually rose.

Ratios

Analyst calculations from the DART data above. ROE and ROA use year-end balances. ROIC uses NOPAT at the effective tax rate over equity plus debt less cash and deposits.

Commentary. Return ratios are diluted by excess cash. Equity of KRW 183.6 bn carries about KRW 75.7 bn of liquid assets earning low single-digit interest. Excluding net cash, the operating business earns a materially higher return. The lengthening of the cash conversion cycle in FY2025, to 84 days from 68, came from lower payables days and slightly higher inventory days. It is a modest negative that partially reversed in 1H26 as payables rose to KRW 12.3 bn.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsRepresentative productsSegment revenue FY2023–FY2025

Reagent

General, analytical, diagnostic and specialty reagents; high-purity, HPLC and electronic-grade solvents; resale of global-brand reagents

Alcohols, acetonitrile, THF, ethyl acetate, n-hexane, methanol; pH standards, volumetric solutions, Karl Fischer reagents, heavy-metal and pesticide-residue test reagents

Not publicly disclosed in reviewed sources

Pharmaceutical raw materials (API)

Excipient-type raw materials and APIs for finished-drug makers

Benzyl alcohol, acetamide and related pharmacopoeia-grade materials (examples per Morningstar)

Not publicly disclosed in reviewed sources

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2021FY2022FY2023FY2024FY2025

Total revenue (KRW Bn)

88.996.693.392.3108.1

YoY growth (%)

10.98.6-3.4-1.017.1

Group Entities

EntityRelationshipStakeLatest total assetsLatest net incomeNotes

Daejung Chemicals & Metals Co., Ltd.

Listed parent / operating company

—

KRW 210.7 bn (FY2025)

KRW 13.5 bn (FY2025)

Reports on a separate basis

SK Chemicals Daejung Co., Ltd.

Joint venture / associate (equity method)

50%

KRW 17.5 bn

KRW 1.05 bn

Formed 2020 with SK Chemicals (50%); high-purity solvents and reagents

Polus Co., Ltd. (㈜폴루스)

Minority investment

0.3%——

Unlisted; business not described in reviewed filings summary

“—” = not publicly disclosed.

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

88.996.693.392.3108.1

Cost of sales (KRW Bn)

71.275.372.073.185.5

Gross profit (KRW Bn)

17.721.321.319.222.6

Operating income (KRW Bn)

7.911.611.08.511.2

Net income (KRW Bn)

8.413.713.09.713.5

EPS basic and diluted (KRW)

1,1771,9161,8071,3501,889

Dividend per share (KRW)

300400450420475

Revenue growth (%)

10.98.6-3.4-1.017.1

Gross margin (%)

19.922.122.820.820.9

Operating margin (%)

8.912.011.89.210.3

Net margin (%)

9.514.213.910.512.5

Dividend payout ratio (%)

2521253125

Financial Analysis

Line item (FY2025)KRW Bn

Revenue

108.1

Cost of sales

85.5

of which raw materials

41.4

of which labour

5.5

of which depreciation

3.1

Gross profit

22.6

SG&A

11.4

of which salaries

4.9

of which freight

1.5

of which R&D expense

1.8

of which commissions

1.1

Operating income

11.2

Net financial income

3.6

of which interest income

2.8

of which interest expense

0.2

Associate-related gains (net)

1.5

Other non-operating (net)

0.3

Pre-tax income

16.6

Income tax

3.0

Effective tax rate (%)

18.2

Net income

13.5

EBITDA (operating income + D&A of c.3.5; analyst calculation)

14.7

Income Statement and Margin Analysis (%)

MetricFY2016FY2017FY2018FY2019FY2020

Revenue (KRW Bn)

60.966.573.879.680.2

Operating income (KRW Bn)

8.49.09.210.410.1

Net income (KRW Bn)

7.57.310.06.18.9

Gross margin (%)

25.525.124.223.923.2

Operating margin (%)

13.813.612.513.012.6

Dividend per share (KRW)

250270300300300

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Analysis — Revenue CAGR FY2021–FY2025

MeasureValue

Revenue CAGR FY2021–FY2025 (4 years)

5.0%

Revenue CAGR FY2016–FY2025 (9 years)

6.6%

Operating income CAGR FY2021–FY2025

9.1%

Net income CAGR FY2021–FY2025

12.6%

DPS 5-year growth rate (ETF Shopping)

9.6% p.a.

Income Statement

Metric (KRW Bn)Q2 2025 (derived)Q2 2026YoY change

Revenue

27.032.3+19.6%

Operating income

2.65.3+104%

Net income

2.34.8+111%

Income Statement and Per-Share Data (TTM Jun-2025–TTM Jun-2026)

Trailing-twelve-month metric (KRW Bn)TTM Jun-2025TTM Dec-2025TTM Jun-2026

Revenue

97.0108.1119.3

Gross profit

19.622.627.1

Operating income

8.911.215.9

Pre-tax income

10.216.621.9

Net income

9.013.517.0

EPS (KRW)

1,2541,8842,370

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025

Total assets (KRW Bn)

173.8196.3202.2210.7

Current assets (KRW Bn)

74.489.588.3108.6

Cash and cash equivalents (KRW Bn)

28.410.820.931.0

Short-term financial instruments (KRW Bn)

18.050.439.644.7

Trade receivables (KRW Bn)

15.116.414.317.5

Inventories (KRW Bn)

12.010.511.614.3

Property, plant and equipment (KRW Bn)

83.694.491.689.7

of which land (KRW Bn)

40.649.949.949.9

Intangible assets (KRW Bn)

0.80.91.41.2

Goodwill (KRW Bn)

0000

Investment in associates (KRW Bn)

8.17.95.87.0

Current liabilities (KRW Bn)

23.122.722.220.6

Short-term borrowings (KRW Bn)

8.98.98.96.9

Long-term borrowings (KRW Bn)

0000

Total debt (KRW Bn)

8.98.98.96.9

Net debt (KRW Bn; negative means net cash)

-37.5-52.3-51.6-68.8

Total liabilities (KRW Bn)

27.229.729.127.1

Total equity (KRW Bn)

146.6166.6173.0183.6

Retained earnings (KRW Bn)

95.6105.7112.1122.6

Working capital (KRW Bn)

51.366.866.188.0

Book value per share (KRW)

20,39323,17324,06725,539

Liabilities-to-equity (%)

18.617.816.814.7

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Net change in cash and equivalents (KRW Bn)

3.5-8.3-17.610.110.3

Dividends declared for the year (KRW Bn)

2.22.93.23.03.4

Share buybacks (KRW Bn)

00000

Cash-flow item (KRW Bn)

Cash-flow item (KRW Bn)FY2025TTM Jun-2026

Operating cash flow

10.016.0

of which working-capital change

-5.3-2.9

of which interest received

2.62.7

of which income tax paid

-2.1-2.9

Capex (PP&E purchases)

1.53.8

Free cash flow (OCF minus capex)

8.512.2

Dividends paid

3.03.4

Borrowings repaid

2.02.0

Investing cash flow (incl. net deposit movements)

5.42.1

Financing cash flow

-5.1-5.5

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE (%)

9.37.85.67.4

ROA (%)

7.96.64.86.4

Current ratio (x)

3.223.943.985.27

Debt to equity (%)

6.15.35.13.8

Asset turnover (x)

0.560.480.460.51

Days sales outstanding

57645759

Days inventory outstanding

58535861

Days payables outstanding

42474736

Cash conversion cycle (days)

73706884

Single-period ratios (FY2025 unless stated)

Value

———

ROIC (NOPAT KRW 9.2 bn / invested capital KRW 114.8 bn)

about 8.0%

———

Net debt / EBITDA

Net cash (−4.7x)

———

Interest coverage (operating income / interest expense)

about 47x

———

ROE TTM Jun-2026 (ValueLine)

9.0%———

Region (FY2025, Indicative) Overview

Region (FY2025, indicative)Share of revenueBasis

South Korea (domestic)

About 97–99%

Implied from ValueLine export series

Exports (destinations not disclosed)

About 1–3%

ValueLine export series; destinations not disclosed

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025

Year-end share price (KRW)

16,05016,72012,88013,280

Year-end market cap (KRW Bn)

115.4120.292.695.5

Year-end P/E (x)

8.49.39.57.0

Year-end P/B (x)

0.790.720.540.52

Performance Details

Performance (to 16–20 Oct 2026)ReturnBasis

1 month

+0.3%

ETF Shopping

6 months

+3.2%

ETF Shopping

1 year

+14.6%

ETF Shopping (price only)

About 3 years (vs. end-2023 close of KRW 16,720)

About −14%

Analyst calculation

About 5 years (vs. 10 Aug 2021 intraday KRW 28,550)

About −49%

Analyst calculation; 2021 level reflected a speculative SK-theme spike

52-week range

KRW 12,220–15,060

ETF Shopping

Valuation Multiples

MultipleDaejung (Oct 2026)SoulbrainDongjin Semichem

P/E (TTM)

6.1x (ValueLine); 7.7x on FY2025 EPS (ETF Shopping)

32.6x21.6x

P/B

0.55x——

EV/Sales (FY2025)

About 0.33x

——

EV/EBITDA (FY2025)

About 2.4x

——

EV/EBITDA (TTM Jun-26, EBITDA about KRW 19.5 bn)

About 1.4x

——

Dividend yield

About 3.3%

0.70%1.56%

Per-Share Data and Dividends & Capital Returns

MetricFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Dividend per share (KRW)

250270300300300300400450420475

Total dividend (KRW Bn)

1.51.72.12.12.12.22.93.23.03.4

Payout ratio (%)

20232135242521253125

Analyst Conclusions

Management guidance and consensus

Management provides no formal guidance, and no consensus estimates exist. A run-rate view based on disclosed data:

  • TTM revenue of KRW 119.3 bn and TTM operating income of KRW 15.9 bn to June 2026.

  • If 2H26 matches 2H25, FY2026 revenue would be about KRW 119 bn and operating income about KRW 16 bn.

  • If Q2 2026 momentum persists (Q2 revenue of KRW 32.3 bn annualizes to about KRW 129 bn), upside to these figures is plausible.

These are analyst extrapolations, not forecasts by the company.

Bull case

  1. Earnings inflection with operating leverage. TTM operating margin expanded from about 9.2% (TTM Jun-2025) to 13.3% (TTM Jun-2026) on nearly flat SG&A. Sustained volume could lift operating income toward KRW 18–20 bn.

  2. Asset-backed downside protection. Net cash of KRW 76.6 bn plus land at cost of KRW 49.9 bn plus the associate stake of KRW 6.4 bn total about KRW 133 bn, well above the KRW 105 bn market cap. Shares trade at 0.55x book and about 1.4x TTM EV/EBITDA.

  3. Value-up and dividend catalysts. High-dividend company status and a 9.6% five-year DPS CAGR make a DPS increase to about KRW 550–600 plausible on TTM EPS of KRW 2,370 at a 25% payout. Samchun's stake may also attract attention to the discount.

Bear case

  1. Structural margin erosion. Gross margin fell from 25.5% to about 21% over FY2016–FY2025, and merchandise is 38% of revenue. 1H26 gains may reflect cyclical solvent pricing rather than durable mix improvement.

  2. Capital misallocation and governance discount. ROE has stayed below 10% for four years, cash keeps accumulating, buybacks are absent and family control is 51.37%. These suggest the valuation discount may persist regardless of earnings.

  3. Working capital and cyclicality. The 30% inventory build in 1H26 and an 84-day cash conversion cycle create risk of write-downs or margin give-back if demand normalizes, as in FY2023–FY2024 when revenue fell two years running.

Key catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorable
About 14 Nov 2026 (historical pattern)Q3 2026 report: confirmation of the Q2 margin step-up and of inventory normalization
31 Dec 2026Dividend record date
About late Feb 2027FY2026 DPS decision: test of value-up commitment
About mid-Mar 2027FY2026 annual report: segment detail, capex plans, JV results, purpose of the 1H26 construction-in-progress project
OngoingSamchun Pure Chemical stake: any change of purpose, increase or commercial tie-up
OngoingSK Chemicals Daejung growth in semiconductor and OLED solvents
OngoingFeedstock price trends for THF, ethyl acetate, acetonitrile and n-hexane; KRW exchange rate
OngoingAny buyback or cancellation to address the 0.55x P/B

Concluding analyst verdict

Daejung Chemicals & Metals is a well-capitalized, consistently profitable but under-followed niche chemical supplier. After two flat years, it entered a clear earnings upswing in FY2025 and 1H26. FY2025 revenue reached a record KRW 108.1 bn. Trailing-twelve-month operating income to June 2026 of KRW 15.9 bn is roughly 40% above the FY2025 level. A largely fixed SG&A base is converting incremental volume into profit at high rates. The balance sheet is exceptionally conservative, with net cash of about KRW 77 bn at mid-2026 equivalent to roughly three-quarters of the market capitalization. Land is carried at historical cost, and the company has a 50% stake in a profitable joint venture with SK Chemicals.

The investment debate is therefore less about solvency or earnings quality than about capital allocation and the durability of margins. On the positive side, an enterprise value of only about KRW 28–36 bn against TTM EBITDA of about KRW 19.5 bn implies the market ascribes little value to the operating business. The new value-up framework and high-dividend tax status give management a reason to keep raising dividends. On the negative side, the gross-margin decline since FY2016, the heavy reliance on resale merchandise, low R&D intensity and single-digit ROE explain the persistent discount. Family control at 51.37%, minimal disclosure and zero analyst coverage limit any catalyst for re-rating.

The June 2026 entry of competitor Samchun Pure Chemical as a 5.74% holder adds an unpredictable strategic element. On balance, the evidence supports characterizing Daejung as a deep-value, asset-backed small cap with improving fundamentals. Upside depends on management converting earnings momentum into higher, more predictable shareholder returns: sustained payout increases, buybacks or productive deployment of surplus cash into higher-margin electronic-grade capacity. Investors should treat the Q3 2026 results and the FY2026 dividend decision as the decisive tests of whether the 1H26 inflection is durable and whether governance will narrow the valuation gap.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / education / ageFY2025 compensation

Song Young-jun (송영준)

CEO and Representative Director

Not disclosed in reviewed sources

Not disclosed; related party of controlling shareholder; holds 14.36%

KRW 0.57 bn (only individual disclosed; disclosure threshold KRW 0.5 bn)

Song Ki-seop (송기섭)

———

Below disclosure threshold or not disclosed

Other directors and auditor

Not disclosed in reviewed sources

——

Average KRW 0.25 bn per director or auditor (5 persons)

“—” = not publicly disclosed.

Major Shareholders

ShareholderTypeStakeDate

Song Ki-seop

Largest shareholder

26.90%

End-FY2025

Song Young-jun

Related party (CEO)

14.36%

End-FY2025

Song Young-jae

Related party

10.11%

End-FY2025

Controlling group total

—

51.37%

Unchanged Dec-2021 to Dec-2025

Samchun Pure Chemical Co., Ltd.

Corporate (competitor)

5.74%

Short-form bulk-holding report filed 26 Jun 2026

National Pension Service

Institution

1.00%

End-2024 (1.11% end-2023)

Minority shareholders (10,963 holders)

Retail and other

42.99%

End-FY2025

Treasury shares

Company

About 0.24%

2026

Competitive Landscape

Key Competitors

CompetitorArea of overlapOwnership / listingRelative positioning

Samchun Pure Chemical (삼전순약공업)

Laboratory reagents, solvents, API raw materials

Private (Korea); founded 1969

Closest domestic peer; markets about 6,000 own-produced items and about 25,000 imported items, with a large hazardous-materials logistics center and a third plant (Jincheon) completed in 2020 (company profile, 2022). Now a 5.74% Daejung holder.

Duksan Pure Chemicals (덕산약품공업)

Laboratory reagents and solvents

Private (Korea)

—

Merck KGaA (Sigma-Aldrich / Supelco)

Global analytical reagents, HPLC solvents

Listed (Germany)

Global leader in research chemicals; premium brand

Thermo Fisher Scientific (Fisher Chemical, Acros, Alfa Aesar legacy)

Lab chemicals, solvents

Listed (US)

Global scale distributor and manufacturer

Avantor (J.T. Baker, VWR)

Lab chemicals, high-purity solvents

Listed (US)

Global; strong in bioprocess and electronic grades

Fujifilm Wako Pure Chemical

Reagents, electronic chemicals

Subsidiary of Fujifilm (Japan)

Strong Japanese reagent brand

Kanto Chemical / Junsei Chemical

Reagents, electronic-grade chemicals

Private (Japan)

Japanese reagent houses active in Korea

Honeywell (Burdick & Jackson)

HPLC and electronic solvents

Listed (US)

Specialist high-purity solvents

Soulbrain

Electronic-grade chemicals for semiconductors

Listed (KOSDAQ: 357780)

Much larger electronic-chemicals player; cited by KoalaGains as competitor in semiconductor chemicals

SK Specialty (formerly SK Materials)

Semiconductor specialty gases and chemicals

SK Group

Cited by KoalaGains as competitor in semiconductor chemicals

Kukjeon Pharm (국전약품)

API raw materials; expanding into electronic materials

Listed (KOSDAQ)

Peer in API and electronic-material diversification; 1H26 revenue KRW 75.2 bn, operating income KRW 4.2 bn (Daily Pharm)

Peer Comparison FY2025

MetricDaejung Chemicals & MetalsKukjeon PharmSoulbrainDongjin Semichem

Latest revenue

KRW 108.1 bn (FY2025)

KRW 75.2 bn (1H26 only)

——

Revenue growth

+17.1% (FY2025)

+5% (1H26 YoY)

——

Operating margin

10.3% (FY2025); 13.3% (TTM Jun-26)

About 5.6% (1H26)

——

R&D intensity

About 1.6%

———

P/E

6.1x (TTM)

—32.6x21.6x

Dividend yield

About 3.3%

—0.70%1.56%

Recent Developments

The company does not issue frequent press releases, and coverage is limited to regulatory filings and data-service updates. All verifiable items are listed.

Company Snapshot

$76.1M

Revenue

201

Employees

1968

Founded

Siheung, South Korea

Headquarters

SWOT Analysis

Strengths

  • Fortress balance sheet. Net cash of KRW 68.8 bn at FY2025 (KRW 76.6 bn at 1H26) against a market cap of about KRW 105 bn; total borrowings only KRW 6.9 bn (DART via ValueLine).
  • Record and accelerating earnings. FY2025 revenue of KRW 108.1 bn (+17.1%) and operating income of KRW 11.2 bn (+31.9%). Q2 2026 operating income of KRW 5.3 bn was roughly double the prior-year quarter.
  • Consistent profitability. Operating income has been positive in every year FY2016–FY2025, ranging from KRW 7.9 bn to KRW 11.6 bn.
  • Broad catalogue and blue-chip customer base. About 2,000 own products and 20,000 resale items (eBest); customers include LG Chem, Hyosung, Chong Kun Dang and Celltrion (DART).
  • Rising, reliable dividends. DPS grew from KRW 250 (FY2016) to KRW 475 (FY2025), with one cut in 10 years; 5-year DPS CAGR 9.6% (ETF Shopping).
  • Strategic partnership with SK Chemicals. 50:50 JV with latest net income of KRW 1.05 bn and total assets of KRW 17.5 bn (FY2025 annual report summary).

Weaknesses

  • Low R&D intensity. R&D of KRW 1.77 bn was about 1.6% of FY2025 revenue (ValueLine).
  • Declining structural gross margin. Gross margin fell from 25.5% (FY2016) to 20.9% (FY2025) (ETF Shopping).
  • High reliance on low-margin merchandise. Resale was 38% of 2Q26 revenue (Butler).
  • Weak capital efficiency. ROE of 5.6–9.3% over FY2022–FY2025, depressed by idle cash (analyst calculation).
  • Limited disclosure and investor outreach. No segment financials in public summaries, no IR calls and zero analyst coverage (StockHub: zero consensus reports).
  • Domestic concentration. Exports are an estimated 1–3% of revenue (ValueLine series).

Opportunities

  • High-purity electronic solvents. Demand from advanced semiconductors and OLED, accessible via the SK Chemicals JV (Dealsite, 2020).
  • Pharma R&D expansion in Korea. This drives HPLC solvent and reagent demand (eBest momentum factor).
  • Value-up regime. High-dividend company tax status (Mar 2026 plan) could broaden the investor base and narrow the P/B discount from 0.55x.
  • Deployment of excess cash. About KRW 83.5 bn of liquidity at 1H26 could fund capacity, M&A or higher shareholder returns.
  • Operating leverage. SG&A was nearly flat (KRW 10.7 bn to KRW 11.2 bn TTM) while revenue rose about 23%, taking TTM operating margin to 13.3%.
  • Import substitution. Electronic-materials localization was flagged by eBest as a key driver.

Threats

  • Competitor stake. Samchun Pure Chemical acquired 5.74% (June 2026), creating uncertainty over intentions and competitive dynamics.
  • Feedstock inflation. Raw materials of KRW 41.4 bn were about 48% of FY2025 cost of sales (ValueLine).
  • Global brand competition. Multinational reagent suppliers such as Merck, Thermo Fisher and Avantor, with superior scale and certified grades, compete for the high-purity segment.
  • Working-capital strain. Inventory rose 30% to KRW 18.6 bn in 1H26, and the cash conversion cycle lengthened to 84 days in FY2025 (analyst calculation).
  • Chemical safety and environmental regulation. Korea's Chemical Substances Control Act and K-REACH regimes raise compliance costs for multi-SKU reagent makers. This is an industry-wide factor; no company-specific case was found.
  • Pharma pricing pressure. Korean drug-price policy can pressure API raw-material margins. This is an industry-wide factor; no company-specific case was found.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
14 May 2025Q1 2025 quarterly report filedStart of FY2025 recovery; TTM revenue rising from KRW 92.3 bn
30 Jun 2025Half-year end; TTM revenue KRW 97.0 bn, TTM net income KRW 9.0 bnSimply Wall St and ValueLine trailing data
14 Aug 20251H25 half-year report filedContinued top-line growth
14 Nov 2025Q3 2025 quarterly report filed; TTM revenue KRW 104.1 bn, TTM operating income KRW 10.2 bnMargins recovering
30 Dec 2025Ex-dividend date for FY2025—
31 Dec 2025FY2025 year end: revenue KRW 108.1 bn (record), net cash KRW 68.8 bnRecord revenue year
24 Feb 2026Board approves FY2025 dividend of KRW 475 per share (KRW 3.4 bn, +13.1%)Restores dividend growth after FY2024 cut
18 Mar 2026FY2025 annual report filed: revenue +17.1%, operating income +31.9% to KRW 11.2 bn, net income KRW 13.5 bnBreakout from two-year stagnation
26 Mar 2026Annual general meeting heldRoutine; resolutions not detailed in reviewed sources
26 Mar 2026Voluntary Corporate Value-up Plan disclosed; high-dividend company status claimed for tax purposesPositions the stock for dividend-oriented investors under Korea's separate dividend-taxation regime
23 Apr 2026FY2025 dividend paid—
14 May 2026Q1 2026 report filed; TTM revenue KRW 113.9 bn, TTM operating income KRW 13.2 bnAcceleration
30 Jun 2026Half-year end; inventories KRW 18.6 bn (+30% vs FY2025); construction in progress KRW 1.5 bnSignals volume build and modest new capex
26 Jun 2026Samchun Pure Chemical files 5.74% short-form bulk-holding reportCompetitor becomes second-largest outside holder; strategic interpretation unconfirmed
14 Aug 20261H26 half-year report filed: Q2 revenue KRW 32.3 bn (about +20% YoY), operating income KRW 5.3 bn (about 2x YoY), net income KRW 4.8 bnStrongest quarterly profit in available record
14 Aug 2026TTM to June 2026: revenue KRW 119.3 bn, operating income KRW 15.9 bn, net income KRW 17.0 bn, TTM EPS KRW 2,370Valuation compresses to about 6x TTM earnings
16 Oct 2026Shares close at KRW 14,550; 52-week range KRW 12,220–15,060; 1-year return +14.6%Shares lag earnings growth
20 Oct 2026Shares at KRW 14,430 (intraday); P/E 6.1x, P/B 0.55x (ValueLine)Deep-value valuation persists

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment: Total revenue rose from KRW 88.9 Bn in FY2021 to KRW 108.1 Bn in FY2025.
Daejung Chemicals & Metals Co., Ltd. — Revenue by Segment
Series (KRW Bn)FY2021FY2022FY2023FY2024FY2025
Total revenue88.996.693.392.3108.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. DART (Financial Supervisory Service) filings: annual reports FY2021–FY2025 (rcpNo 20220316000108, 20230315000243, 20240318000183, 20250318000203, 20260318000412); dividend decision 20260224900197; Value-up Plan 20260326900387; quarterly and half-year reports through 1H26. Accessed via ValueLine/DataHero, ETF Shopping and Butler compilations, because DART blocks automated access.
  2. ValueLine (valueline.co.kr): income statement, balance sheet, cash flow and business summary for 120240 (26.2Q update, accessed 20 Oct 2026).
  3. ETF Shopping (etfshopping.com): company, shareholder, employee, dividend and 10-year financial pages for 120240 (updated Mar–Oct 2026).
  4. Butler (butler.works): product mix and filing list for 120240.
  5. Dealsite: SK Chemicals–Daejung JV reports (26 and 31 Aug 2020).
  6. Financial News (fnnews.com): Daejung feature article (10 Aug 2021).
  7. eBest Investment & Securities: Daejung company brief (15 Jul 2019).
  8. Morningstar Australia and Simply Wall St company profiles (2025–2026).
  9. TipRanks and StockHub quote pages (2026).
  10. Samchun Pure Chemical corporate profile (2022, via Kookmin University career portal).
  11. Daily Pharm: Kukjeon Pharm 1H26 results article (2026).
  12. KoalaGains: Daejung competitive analysis page.
  13. GII Korea market-report summaries on semiconductor-grade solvents (2026).

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.